JC

Jarugula China Venkayamma

Active Director Director DIN 11208965
DIN 11208965 First appointment Jul 2025 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jul 2025
Shareholding value β€’β€’β€’β€’ Premium profile

About Jarugula China Venkayamma

Data last updated:

Jarugula China Venkayamma is a Director at Crestone Pharmaceutical Private Limited (since 2025). The company operates in Pharma.

DIN 11208965
Primary Designation Director
Industry Pharma
First Appointment 23 Jul 2025
Oldest Company Age 1 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director23 Jul 20252025Active

Board colleagues of Jarugula China Venkayamma

Directorship timeline

Open interactive timeline →
Crestone Pharmaceutical Private Limited
Premium access

Shareholding and investment profile for Jarugula China Venkayamma

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Jarugula China Venkayamma

Jarugula China Venkayamma currently holds 1 directorship: Crestone Pharmaceutical Private Limited (Director, since 23 Jul 2025).

Jarugula China Venkayamma was first appointed on 23 Jul 2025 as Director at Crestone Pharmaceutical Private Limited.

The current boards of Jarugula China Venkayamma's companies include Ankamma Devi Kotagiri (Crestone Pharmaceutical Private Limited), Botuku Lavanya (Crestone Pharmaceutical Private Limited), Jyothi Sirigiri (Crestone Pharmaceutical Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available